This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boston Scientific Begins Patient Enrollment In U.S. Clinical Trial For Use Of Vercise™ DBS System In Treatment Of Parkinson's Disease

NATICK, Mass., June 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial.  INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise DBS System for the treatment of Parkinson's disease.

The Vercise DBS System is a neurostimulation device that delivers electrical signals to specific areas within the brain through individual lead contacts.  It is the only system that allows physicians to adjust the current flow in fine increments based on patient needs.

The first patient was implanted at Cedars-Sinai in Los Angeles by a team led by Michele Tagliati, M.D., director, Movement Disorders Program, and Adam Mamelak, M.D., FACS, FAANS, director, Functional Neurosurgery. 

"The Vercise DBS System offers the promise to customize stimulation control in ways never before possible," said Dr. Tagliati.

"The indications for deep brain stimulation are rapidly expanding, while innovations in the devices used for this therapy have been slower," said Philip A. Starr, M.D., PhD, co-principal director, Functional Neurosurgery Program, University of California, San Francisco and co-principal investigator of the trial. "The launch of this trial heralds advanced innovation in device development which is greatly needed."

"The Vercise DBS System has the ability to deliver stimulation in a precise manner due to multiple independent current control which represents a significant opportunity for DBS therapy in the treatment of Parkinson's disease," said Jerry Vitek, M.D., professor and chair, Department of Neurology, University of Minnesota and co-principal investigator of the trial. "The technology offered with this system is designed to provide a flexible programming platform that is expected to improve our patients' quality of life."

The Vercise DBS System has both CE Mark and TGA (Australia Therapeutic Goods Administration) approval and is available for sale in Europe, Israel and Australia.  In the U.S., the Vercise DBS System is investigational and not available for use or sale. 

Parkinson's disease is a progressive neurodegenerative disorder that affects about one million Americans and seven to 10 million people worldwide, according to the World Health Organization and the Parkinson's Disease Foundation. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs